nach oben

Erschienen in:

01.10.2014 | Original Article

A tetravalent dengue vaccine containing a mix of domain III-P64k and domain III-capsid proteins induces a protective response in mice

verfasst von: Alienys Izquierdo, Angélica García, Laura Lazo, Lázaro Gil, Ernesto Marcos, Mayling Alvarez, Iris Valdés, Lisset Hermida, Gerardo Guillén, María G. Guzmán

Erschienen in: Archives of Virology | Ausgabe 10/2014

Einloggen, um Zugang zu erhalten

Abstract

Recombinant fusion proteins containing domain III of the dengue virus envelope protein fused to the P64k protein from Neisseria meningitidis and domain III of dengue virus type 2 (D2) fused to the capsid protein of this serotype were immunogenic and conferred protection in mice against lethal challenge, as reported previously. Combining the domain III-P64k recombinant proteins of dengue virus types 1, 3 and 4 (D1, D3, and D4) with the domain III-capsid protein from D2, we obtained a novel tetravalent formulation containing different antigens. Here, the IgG and neutralizing antibody response, the cellular immune response, and the protective capacity against lethal challenge in mice immunized with this tetravalent formulation were evaluated. The neutralizing antibody response obtained against D1, D2 and D3, together with the high levels of IFNγ secretion induced after stimulation with the four dengue serotypes, supports the strategy of using a new tetravalent formulation containing domain III of the envelope protein fused to the capsid protein of each dengue virus serotype.

Guzman MG, Kouri G (2002) Dengue: an update. Lancet Infect Dis 2(1):33–42PubMedCrossRef

Wallace D, Canouet V, Garbes P, Wartel TA (2013) Challenges in the clinical development of a dengue vaccine. Curr Opin Virol. doi:10.1016/j.coviro.2013.05.014 PubMed

Halstead SB, O’Rourke EJ (1977) Antibody-enhanced dengue virus infection in primate leukocytes. Nature 265(5596):739–741PubMedCrossRef

Rothman AL (2010) Cellular immunology of sequential dengue virus infection and its role in disease pathogenesis. Curr Top Microbiol Immunol 338:83–98PubMed

Swaminathan S, Batra G, Khanna N (2010) Dengue vaccines: state of the art. Expert Opin Ther Pat 20(6):819–835PubMedCrossRef

Hermida L, Rodriguez R, Lazo L, Bernardo L, Silva R, Zulueta A, Lopez C, Martin J, Valdes I, Del Rosario D, Guillen GE, Guzman MG (2004) A fragment of the Envelope protein from Dengue-1 virus, fused in two different sites of the meningococcal P64k protein carrier, induces a functional immune response in mice. Biotechnol Appl Biochem 39(1):107–114PubMedCrossRef

Hermida L, Rodriguez R, Lazo L, Silva R, Zulueta A, Chinea G, Lopez C, Guzman MG, Guillen G (2004) A dengue-2 Envelope fragment inserted within the structure of the P64k meningococcal protein carrier enables a functional immune response against the virus in mice. J Virol Methods 115(1):41–49 pii: S0166093403003070PubMedCrossRef

Izquierdo A, Bernardo L, Martin J, Santana E, Hermida L, Guillen G, Guzman MG (2008) Serotype-specificity of recombinant fusion proteins containing domain III of dengue virus. Virus Res 138(1–2):135–138. doi:10.1016/j.virusres.2008.08.008 PubMedCrossRef

Lazo L, Zulueta A, Hermida L, Blanco A, Sanchez J, Valdes I, Gil L, Lopez C, Romero Y, Guzman MG, Guillen G (2009) Dengue-4 envelope domain III fused twice within the meningococcal P64k protein carrier induces partial protection in mice. Biotechnol Appl Biochem 52(Pt 4):265–271PubMedCrossRef

10.

Bernardo L, Izquierdo A, Alvarez M, Rosario D, Prado I, Lopez C, Martinez R, Castro J, Santana E, Hermida L, Guillen G, Guzman MG (2008) Immunogenicity and protective efficacy of a recombinant fusion protein containing the domain III of the dengue 1 envelope protein in non-human primates. Antivir Res 80(2):194–199PubMedCrossRef

11.

Hermida L, Bernardo L, Martin J, Alvarez M, Prado I, Lopez C, Sierra Bde L, Martinez R, Rodriguez R, Zulueta A, Perez AB, Lazo L, Rosario D, Guillen G, Guzman MG (2006) A recombinant fusion protein containing the domain III of the dengue-2 envelope protein is immunogenic and protective in nonhuman primates. Vaccine 24(16):3165–3171. doi:10.1016/j.vaccine.2006.01.036 PubMedCrossRef

12.

Valdes I, Bernardo L, Gil L, Pavon A, Lazo L, Lopez C, Romero Y, Menendez I, Falcon V, Betancourt L, Martin J, Chinea G, Silva R, Guzman MG, Guillen G, Hermida L (2009) A novel fusion protein domain III-capsid from dengue-2, in a highly aggregated form, induces a functional immune response and protection in mice. Virology 394(2):249–258. doi:10.1016/j.virol.2009.08.029 PubMedCrossRef

13.

Zulueta A, Hermida L, Lazo L, Valdes I, Rodriguez R, Lopez C, Silva R, Rosario D, Martin J, Guzman MG, Guillen G (2003) The fusion site of envelope fragments from each serotype of Dengue virus in the P64k protein, influence some parameters of the resulting chimeric constructs. Biochem Biophys Res Commun 308(3):619–626PubMedCrossRef

14.

Marcos E, Gil L, Lazo L, Izquierdo A, Brown E, Suzarte E, Valdés I, García A, Méndez L, Guzmán MG, Guillén G, Hermida L (2013) Purified and highly aggregated chimeric protein DIIIC-2 induces a functional immune response in mice against dengue 2 virus. Arch Virol 158(1):225–230PubMedCrossRef

15.

Clarke DH, Casals J (1958) Techniques for Hemagglutination and Hemagglutination-inhibition with arthropod-borne viruses. Am J Trop Med Hyg 7:561–573PubMed

16.

Morens DM, Halstead SB, Repik PM, Putvatana R, Raybourne N (1985) Simplified plaque reduction neutralization assay for dengue viruses by semimicro methods in BHK-21 cells: comparison of the BHK suspension test with standard plaque reduction neutralization. J Clin Microbiol 22(2):250–254PubMedPubMedCentral

17.

Alvarez M, Rodriguez-Roche R, Bernardo L, Morier L, Guzman G (2005) Improved dengue virus plaque formation on BHK21 and LLCMK2 cells: evaluation of some factors. Dengue Bull 29:1–9

18.

Brandler S, Ruffie C, Najburg V, Frenkiel MP, Bedouelle H, Desprès P, Tangy F (2010) Pediatric measles vaccine expressing a dengue tetravalent antigen elicits neutralizing antibodies against all four dengue viruses. Vaccine 28:6730–6739PubMedCrossRef

19.

Lazo L, Gil L, Lopez C, Valdes I, Marcos E, Alvarez M, Blanco A, Romero Y, Falcon V, Guzmán MG, Guillén G, Hermida L (2010) Nucleocapsid-like particles of dengue-2 virus enhance the immune response against a recombinant protein of dengue-4 virus. Arch Virol 155(10):1587–1595PubMedCrossRef

20.

Lazo L, Gil L, López C, Valdés I, Blanco A, Pavón A, Romero Y, Guzmán MG, Guillén G, Hermida L (2012) A vaccine formulation consisting of nucleocapsid-like particles from Dengue-2 and the fusion protein P64k-domain III from Dengue-1 induces a protective immune response against the homologous serotypes in mice. Acta Tropica 124:107–112PubMedCrossRef

21.

Mune M, Rodriguez R, Ramirez R, Soto Y, Sierra B, Rodriguez Roche R, Marquez G, Garcia J, Guillen G, Guzman MG (2003) Carboxy-terminally truncated Dengue 4 virus envelope glycoprotein expressed in Pichia pastoris induced neutralizing antibodies and resistance to Dengue 4 virus challenge in mice. Arch Virol 148(11):2267–2273. doi:10.1007/s00705-003-0167-9 PubMedCrossRef

22.

Simmons M, Murphy GS, Hayes CG (2001) Short report: antibody responses of mice immunized with a tetravalent dengue recombinant protein subunit vaccine. Am J Trop Med Hyg 65(2):159–161PubMed

23.

Edelman R, Wasserman SS, Bodison SA, Putnak RJ, Eckels KH, Tang D, Kanesa-Thasan N, Vaughn DW, Innis BL, Sun W (2003) Phase I trial of 16 formulations of a tetravalent live-attenuated dengue vaccine. Am J Trop Med Hyg 69(6 Suppl):48–60PubMed

24.

Vaughn DW (2000) Invited commentary: dengue lessons from Cuba. Am J Epidemiol 152(9):800–803PubMedCrossRef

25.

Putnak JR, de la Barrera R, Burgess T, Pardo J, Dessy F, Gheysen D, Lobet Y, Green S, Endy TP, Thomas SJ, Eckels KH, Innis BL, Sun W (2008) Comparative evaluation of three assays for measurement of dengue virus neutralizing antibodies. Am J Trop Med Hyg 79(1):115–122PubMed

26.

Guy B, Almond JW (2008) Towards a dengue vaccine: progress to date and remaining challenges. Comp Immunol Microbiol Infect Dis 31(2–3):239–252. doi:10.1016/j.cimid.2007.07.011 PubMedCrossRef

27.

Hombach J, Cardosa MJ, Sabchareon A, Vaughn DW, Barrett AD (2007) Scientific consultation on immunological correlates of protection induced by dengue vaccines report from a meeting held at the World Health Organization 17–18 November 2005. Vaccine 25(21):4130–4139PubMedCrossRef

28.

Shresta S, Kyle JL, Snider HM, Basavapatna M, Beatty PR, Harris E (2004) Interferon-dependent immunity is essential for resistance to primary dengue virus infection in mice, whereas T- and B-cell-dependent immunity are less critical. J Virol 78(6):2701–2710PubMedCrossRefPubMedCentral

29.

Keating R, Yue W, Rutigliano JA, So J, Olivas E, Thomas PG, Doherty PC (2007) Virus-specific CD8+T cells in the liver: armed and ready to kill. J Immunol 178:2737–2745PubMedCrossRef

30.

Welsh RM, Selin LK, Szomolanyi-Tsuda E (2004) Immunological memory to viral infection. Annu Rev Immunol 22:23.1–23.33CrossRef

31.

Mongkolsapaya J, Duangchinda T, Dejnirattisai W, Vasanawathana S, Avirutnan P, Jairungsri A, Khemnu N, Tangthawornchaikul N, Chotiyarnwong P, Sae-Jang K, Koch M, Jones Y, McMichael A, Xu X, Malasit P, Screaton G (2006) T cell responses in dengue hemorrhagic fever: are cross-reactive T cells suboptimal? J Immunol 176(6):3821–3829 pii: 176/6/3821PubMedCrossRef

32.

van der Most RG, Murali-Krishna K, Ahmed R (2003) Prolonged presence of effector-memory CD8 T cells in the central nervous system after dengue virus encephalitis. Int Immunol 15(1):119–125PubMedCrossRef

33.

van Der Most RG, Murali Krishna K, Ahmed R, Strauss JH (2000) Chimeric yellow fever/dengue virus as a candidate dengue vaccine: quantitation of the dengue virus-specific CD8 T-cell response. J Virol 74(17):8094–8101CrossRefPubMedCentral

34.

Gil L, Lopez C, Blanco A, Lazo L, Martin J, Valdes I, Romero Y, Figueroa Y, Guillen G, Hermida L (2009) The cellular immune response plays an important role in protecting against dengue virus in the mouse encephalitis model. Viral Immunol 22(1):23–30. doi:10.1089/vim.2008.0063 PubMedCrossRef

35.

Moi ML, Takasaki T, Kurane I (2013) Efficacy of tetravalent dengue vaccine in Thai schoolchildren. Lancet 30(381):9872

36.

Mota J, Acosta M, Argotte R, Figueroa R, Mendez A, Ramos C (2005) Induction of protective antibodies against dengue virus by tetravalent DNA immunization of mice with domain III of the envelope protein. Vaccine 23(26):3469–3476. doi:10.1016/j.vaccine.2004.12.028 PubMedCrossRef

37.

Lazo L, Hermida L, Zulueta A, Sanchez J, Lopez C, Silva R, Guillen G, Guzman MG (2007) A recombinant capsid protein from Dengue-2 induces protection in mice against homologous virus. Vaccine 25(6):1064–1070. doi:10.1016/j.vaccine.2006.09.068 PubMedCrossRef

38.

Guzman MG, Hermida L, Bernardo L, Ramirez R, Guillen G (2010) Domain III of the envelope protein as a dengue vaccine target. Expert Rev Vaccines 9(2):137–147. doi:10.1586/erv.09.139 PubMedCrossRef

39.

Gil L, Bernardo L, Pavon A, Izquierdo A, Valdes I, Lazo L, Marcos E, Romero Y, Guzman MG, Guillen G, Hermida L (2012) Recombinant nucleocapsid-like particles from dengue-2 induce functional serotype-specific cell-mediated immunity in mice. J Gen Virol 93(Pt 6):1204–1214. doi:10.1099/vir.0.037721-0 PubMedCrossRef

Titel: A tetravalent dengue vaccine containing a mix of domain III-P64k and domain III-capsid proteins induces a protective response in mice
verfasst von: Alienys Izquierdo
Angélica García
Laura Lazo
Lázaro Gil
Ernesto Marcos
Mayling Alvarez
Iris Valdés
Lisset Hermida
Gerardo Guillén
María G. Guzmán
Publikationsdatum: 01.10.2014
Verlag: Springer Vienna
Erschienen in: Archives of Virology / Ausgabe 10/2014
Print ISSN: 0304-8608
Elektronische ISSN: 1432-8798
DOI: https://doi.org/10.1007/s00705-014-2115-2

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

„Überwältigende“ Evidenz für Tripeltherapie beim metastasierten Prostata-Ca.

22.05.2024 Prostatakarzinom Nachrichten

Patienten mit metastasiertem hormonsensitivem Prostatakarzinom sollten nicht mehr mit einer alleinigen Androgendeprivationstherapie (ADT) behandelt werden, mahnt ein US-Team nach Sichtung der aktuellen Datenlage. Mit einer Tripeltherapie haben die Betroffenen offenbar die besten Überlebenschancen.

So sicher sind Tattoos: Neue Daten zur Risikobewertung

22.05.2024 Melanom Nachrichten

Das größte medizinische Problem bei Tattoos bleiben allergische Reaktionen. Melanome werden dadurch offensichtlich nicht gefördert, die Farbpigmente könnten aber andere Tumoren begünstigen.

CAR-M-Zellen: Warten auf das große Fressen

22.05.2024 Onkologische Immuntherapie Nachrichten

Auch myeloide Immunzellen lassen sich mit chimären Antigenrezeptoren gegen Tumoren ausstatten. Solche CAR-Fresszell-Therapien werden jetzt für solide Tumoren entwickelt. Künftig soll dieser Prozess nicht mehr ex vivo, sondern per mRNA im Körper der Betroffenen erfolgen.

Frühzeitige HbA1c-Kontrolle macht sich lebenslang bemerkbar

22.05.2024 Typ-2-Diabetes Nachrichten

Menschen mit Typ-2-Diabetes von Anfang an intensiv BZ-senkend zu behandeln, wirkt sich positiv auf Komplikationen und Mortalität aus – und das offenbar lebenslang, wie eine weitere Nachfolgeuntersuchung der UKPD-Studie nahelegt.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Die Highlights vom Kongress des American College of Cardiology 2024

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 10/2014

Eastern equine encephalitis cases among horses in Brazil between 2005 and 2009

A vesicular stomatitis pseudovirus expressing the surface glycoproteins of influenza A virus

Analysis of the phylogeny of Chinese H9N2 avian influenza viruses and their pathogenicity in mice

Complete genome sequence analysis of an enterovirus 75 isolate from China

Comparison of the replication characteristics of vaccinia virus strains Guang 9 and Tian Tan in vivo and in vitro